High Dose Vitamin C Research

This 2024 systematic review and meta-analysis examined the effects of vitamin C supplementation on outcomes in critically ill patients across randomized controlled trials. The study cast a broader net than sepsis-specific analyses, including patients in ICU settings with various critical conditions.

The meta-analysis found that vitamin C supplementation was associated with significant reductions in ICU length of stay, hospital length of stay, and duration of mechanical ventilation. However, it did not demonstrate a statistically significant reduction in overall mortality. These findings suggest that while vitamin C may improve recovery metrics and resource utilization in ICU settings, its impact on survival remains uncertain.

The authors assessed risk of bias across included studies and found variable quality. They concluded that vitamin C supplementation appears to be a safe and potentially beneficial adjunctive therapy for critically ill patients, particularly for reducing the burden of intensive care. Larger, higher-quality RCTs with standardized dosing protocols are needed to clarify the mortality question.

Systematic review and meta-analysis with trial sequential analysis (TSA) evaluating intravenous vitamin C (IVVC) monotherapy in adult critically ill patients. The study searched four databases from inception through June 2022 without language restrictions, specifically isolating the effect of vitamin C alone (excluding combination therapies like thiamine-hydrocortisone protocols).

Sixteen RCTs with 2,130 participants were included. The primary outcome showed that IVVC monotherapy was associated with a significant reduction in overall mortality (risk ratio 0.73, 95% CI 0.60-0.89, p = 0.002, I-squared = 42%). Subgroup analysis revealed the greatest benefit in trials enrolling patients with baseline mortality above 37.5% (RR 0.65), suggesting high-acuity patients benefit most.

Trial sequential analysis was conducted to account for the risk of random errors from repeated significance testing. The analysis used specific parameters (alpha 5%, beta 10%, relative risk reductions of 30%, 25%, and 20%). Despite the positive mortality signal, the certainty of evidence was rated low by GRADE criteria due to serious risk of bias and inconsistency among studies. The authors concluded that further research is needed to determine optimal timing, dosage, treatment duration, and patient selection.

This systematic review and meta-analysis pooled data from randomized controlled trials examining the effect of intravenous vitamin C on mortality in patients with sepsis. The review included studies published through 2022 and assessed multiple mortality endpoints.

The meta-analysis found that IV vitamin C significantly reduced overall mortality (pooled risk ratio favoring treatment) and 28-day mortality in sepsis patients. However, it did not show a statistically significant benefit for 30-day or 90-day mortality, suggesting the survival benefit may be most pronounced in the short term.

Risk of bias was assessed using the Cochrane tool, and funnel plots were generated to evaluate publication bias. The authors concluded that while short-term mortality benefits exist, longer-term outcomes require further investigation with larger, well-designed RCTs. The heterogeneity across studies was notable, reflecting differences in vitamin C dosing protocols, patient populations, and sepsis severity.

This meta-analysis of randomized controlled trials evaluated the clinical outcomes of intravenous vitamin C therapy in patients with sepsis or septic shock. Published in Critical Care, a high-impact journal, it synthesized evidence from multiple RCTs to assess mortality, ICU length of stay, and other clinical endpoints.

The analysis found that IV vitamin C was associated with reduced short-term mortality and shorter ICU stays in sepsis and septic shock patients. Subgroup analyses suggested that higher vitamin C doses and longer treatment durations may produce greater benefits. The results were particularly notable for septic shock patients, who represent the most critically ill subset.

The authors noted that while the overall evidence supports a potential role for IV vitamin C as an adjunctive therapy in sepsis management, the heterogeneity across included trials and variations in dosing regimens call for standardized, large-scale RCTs to confirm these findings and establish optimal dosing protocols.

Systematic review and meta-analysis of randomized controlled trials examining whether intravenous high-dose vitamin C improves outcomes in sepsis patients. The study was registered at UMIN000040528 and searched EMBASE, Cochrane Central Register, and MEDLINE.

Eleven RCTs encompassing 1,737 patients met inclusion criteria. Using random-effects models, the primary outcome of short-term mortality showed no significant reduction with high-dose IV vitamin C (risk ratio 0.88, 95% CI 0.73-1.06, p = 0.18, I-squared = 29%). However, secondary outcomes were more promising: vitamin C was associated with significantly shorter vasopressor duration and greater Sequential Organ Failure Assessment (SOFA) score decline at 72-96 hours.

The findings suggest that while high-dose IV vitamin C may not reduce mortality on its own in sepsis, it appears to improve organ function markers and hemodynamic stability. Adverse effects were rare, with one study reporting hypernatremia. The results contributed to the ongoing debate about vitamin C as an adjunctive therapy in critical care.

Detailed review of vitamin C's role in supporting various aspects of immune function.

Comprehensive systematic review examining the safety, effectiveness, and pharmacokinetics of intravenous vitamin C (IVC) as a therapy in cancer populations. The review searched MEDLINE, EMBASE, Cochrane Library, CINAHL, and AMED databases from inception through April 2013.

Of 897 identified records, 39 reports covering 37 studies met inclusion criteria, including 2 RCTs, 15 uncontrolled trials, 6 observational studies, and 14 case reports. IVC dosing ranged from 1 to over 200 grams per infusion, typically administered 2-3 times weekly.

The review found that IVC does not appear to increase toxicity or interfere with antitumor effects of standard chemotherapy regimens such as gemcitabine/erlotinib or paclitaxel/carboplatin. IVC appeared beneficial for reducing chemotherapy-related symptoms including fatigue, nausea, insomnia, constipation, and depression. Case reports documented instances of tumor regression and extended disease-free survival, though the authors emphasized that the existing evidence is preliminary and cannot be considered conclusive.

Definitive Cochrane systematic review examining vitamin C for common cold prevention and treatment.

This NIH pharmacokinetic study characterized vitamin C absorption and plasma levels after various oral and IV doses.

Key finding: oral vitamin C absorption is tightly controlled, with plasma levels plateauing around 220 µmol/L even with high oral doses. IV administration bypasses this limit and can achieve much higher concentrations.